MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

108.74 -1.19 (-1.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
News headline image
New Study Validates Guardant Reveal Blood Test’s Effectiveness in Monitoring Chemotherapy Response
From Guardant Health, Inc.
Via Business Wire
News headline image
Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Proposed Public Offering of Common Stock
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025
From Guardant Health, Inc.
Via Business Wire
News headline image
FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company’s Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States
From Guardant Health, Inc.
Via Business Wire
News headline image
Alex M. Azar II Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Host Investor Day on September 24, 2025
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
News headline image
American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story